Terminated PHASE1 INTERVENTIONAL 10-arm NCT05241873

(Concerto) Study of BLU-451 in Advanced Cancers With EGFR Exon 20 Insertion Mutations

Phase I/II Study of BLU-451 in Advanced Cancers With EGFR Exon 20 Insertion Mutations

Sponsor: Blueprint Medicines Corporation

Interventions BLU-451 Carboplatin Pemetrexed

Updated 15 times since 2022 Last updated: Feb 6, 2025 Started: Mar 4, 2022 Primary completion: Jul 31, 2024 Completion: Jul 31, 2024

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Sponsor decision, not related to safety concerns

Other terminated trials from Blueprint Medicines Corporation

More terminations from Blueprint Medicines Corporation

Other Adenocarcinoma trials with similar outcome

Browse all Adenocarcinoma trials

This PHASE1 trial investigates Adenocarcinoma and Antineoplastic Agents and is currently terminated or withdrawn. Blueprint Medicines Corporation leads this study, which shows 15 recorded versions since 2022 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

15 versions recorded

Sep 2025 — Present [monthly]

Terminated PHASE1
Mar 2025 — Sep 2025 [monthly]

Terminated PHASE1

Status: Active Not Recruiting → Terminated · Phase: PHASE1/PHASE2 → PHASE1
Oct 2024 — Mar 2025 [monthly]

Active Not Recruiting PHASE1/PHASE2
Sep 2024 — Oct 2024 [monthly]

Active Not Recruiting PHASE1/PHASE2
Jul 2024 — Sep 2024 [monthly]

Active Not Recruiting PHASE1/PHASE2

Phase: PHASE1_PHASE2 → PHASE1/PHASE2

▶ Show 10 earlier versions

Feb 2024 — Jul 2024 [monthly]

Active Not Recruiting PHASE1_PHASE2

Status: Recruiting → Active Not Recruiting
Nov 2023 — Feb 2024 [monthly]

Recruiting PHASE1_PHASE2
Sep 2023 — Nov 2023 [monthly]

Recruiting PHASE1_PHASE2
Jul 2023 — Sep 2023 [monthly]

Recruiting PHASE1_PHASE2
Jun 2023 — Jul 2023 [monthly]

Recruiting PHASE1_PHASE2
Apr 2023 — Jun 2023 [monthly]

Recruiting PHASE1_PHASE2
Nov 2022 — Apr 2023 [monthly]

Recruiting PHASE1_PHASE2
Sep 2022 — Nov 2022 [monthly]

Recruiting PHASE1_PHASE2
May 2022 — Sep 2022 [monthly]

Recruiting PHASE1_PHASE2

Status: Not Yet Recruiting → Recruiting
Mar 2022 — May 2022 [monthly]

Not Yet Recruiting PHASE1_PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Blueprint Medicines Corporation

Data source: Blueprint Medicines Corporation

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Aurora, United States , Boston, United States , Chicago, United States , Chuo-ku, Japan , Duarte, United States , Fairfax, United States , Houston, United States , Kashiwa, Japan , Los Angeles, United States , New York, United States and 9 more locations